<\/p>\n
Nicip<\/strong> er en oral tablet fra Cipla, der indeholder nimesulide 100 mg<\/strong> — a preferential COX-2 inhibitor NSAID<\/strong> used for short-term symptomatic treatment of acute musculoskeletal pain, primary dysmenorrhoea, and osteoarthritis flare. Standard adult dose: 100 mg twice daily, taken with food<\/strong>, for the shortest necessary duration and a maximum of 15 days<\/strong>. Important regulatory context<\/strong>: nimesulide has been withdrawn from the market in the United States, United Kingdom, Spain, Finland, Israel, Singapore<\/strong> and never approved in Australia or Canada<\/strong> because of cases of fulminant (sometimes fatal) hepatotoxicity<\/strong>. It remains licensed in several European countries and parts of Asia and Latin America with strict use limits: baseline liver function tests before any course<\/strong>, maximum 15-day course<\/strong>, contraindicated in patients younger than 12 years<\/strong>, in pregnancy (especially third trimester), in significant hepatic impairment, in active alcohol use disorder, and in patients with a history of nimesulide-related hepatotoxicity. As with all NSAIDs, additional risks include GI bleed and ulcer, renal impairment, hypertension, and increased cardiovascular event risk. Paracetamol and ibuprofen are usually safer first-line analgesics<\/strong>; nimesulide should be reserved for short-term use when other NSAIDs have failed or are not tolerated.<\/p>\n<\/div>\n \ud83d\udce6 Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy<\/strong><\/a> \u2014 hvis din pakke ikke ankommer inden for 20 hverdage, sender vi en erstatning.<\/p>\n Vores generiske medicin kommer fra WHO-GMP certificerede producenter og sendes verdensomsp\u00e6ndende i diskret, neutral emballage \u2014 ingen medicinnavn p\u00e5 pakkens ydre. Kortbetalinger h\u00e5ndteres af en reguleret processor (kontoudtogsbeskrivelser inkluderer en reguleret betalingsprocessor \u2014 aldrig \u201cMedsBase\u201d eller medicinnavn). Crypto og SEPA bankoverf\u00f8rsel accepteres ogs\u00e5. Hver ordre er d\u00e6kket af vores Reshipment Assurance Policy.<\/p>\n <\/p>\n Nicip is an oral tablet manufactured by Cipla containing nimesulide<\/strong>, a preferential cyclo-oxygenase-2 (COX-2) inhibitor in the sulfonanilide class<\/strong> of non-steroidal anti-inflammatory drugs. Nimesulide was first marketed in the late 1980s; it has analgesic, anti-inflammatory and antipyretic actions broadly similar to other NSAIDs, with relatively rapid onset of pain relief.<\/p>\n Nicip is Cipla's long-stocked branded nimesulide tablet — one of the most familiar names in the regional NSAID space. The 100 mg strength is the standard adult dose, taken twice daily for short-term symptomatic treatment (maximum 15-day course) of acute musculoskeletal pain, painful osteoarthritis flare and primary dysmenorrhoea.<\/p>\n Honest regulatory and safety framing.<\/strong> Nimesulide has had a complicated regulatory history. After clusters of severe and sometimes fatal hepatotoxicity in the early 2000s, several national regulators withdrew the drug from the market: the United States and Australia never approved it; the United Kingdom withdrew it in 1999; Spain in 2002; Finland in 2002; Israel in 2007; and Singapore in 2007. The European Medicines Agency reviewed nimesulide in 2007 and 2011 and confirmed it remained authorised in some European countries with restrictions: maximum 100 mg twice daily, maximum 15-day course, baseline LFTs, contraindicated in children under 12, in significant hepatic impairment, and in pregnancy. India has retained nimesulide on its market with broadly similar (though variably enforced) restrictions. The drug should always be regarded as a second-line analgesic<\/strong> — reserved for patients who have not had adequate response to or cannot tolerate paracetamol, ibuprofen, naproxen or diclofenac.<\/p>\n Nimesulide preferentially inhibits the inducible cyclo-oxygenase-2 (COX-2) enzyme<\/strong> over the constitutive COX-1, blocking conversion of arachidonic acid to prostaglandin H2 and downstream prostaglandins (PGE2, PGI2). The result is reduced inflammation, reduced peripheral pain sensitisation, and reduced fever.<\/p>\n Additional mechanisms beyond COX-2 inhibition that may contribute to clinical effect:<\/p>\n Onset of analgesic effect: 30\u201360 minutter<\/strong> after a single oral dose; peak effect at 2–3 hours. Plasma half-life: 2–5 hours. Twice-daily dosing maintains steady analgesic levels. Metabolised in the liver, principally by CYP2C9.<\/p>\n Within current regulatory restrictions, Nicip is licensed for short-term symptomatic treatment<\/strong> af:<\/p>\n Nicip is ikke<\/strong> appropriate for: routine analgesia, long-term pain management (max 15-day course), fever reduction (paracetamol is safer), pain in children under 12 (contraindicated), pain in pregnancy (contraindicated), or chronic inflammatory disease (other DMARDs and longer-acting NSAIDs are preferred).<\/p>\n Nicip is supplied at 100 mg<\/strong>. Standarddosis for voksne er 100 mg to gange dagligt<\/strong>, taken with food.<\/p>\nHvorfor bestille fra MedsBase<\/h3>\n
What Is Nicip?<\/h2>\n
How Does Nicip Work?<\/h2>\n
\n
\u2014 det forst\u00e6rker den normale fysiologiske respons snarere end at udl\u00f8se en kunstigt.<\/h2>\n
\n
Nicip Dosage and How to Take<\/h2>\n
Dosing rules<\/h3>\n